首页 › 基金 › BRAIDWELL LP › RYTM

BRAIDWELL LP 对 RYTM 的持仓历史

RHYTHM PHARMACEUTICALS INC · 医疗保健

BRAIDWELL LP 在 Q2 2026 的 13F 申报中披露持有 RYTM(RHYTHM PHARMACEUTICALS INC)381,128 股,市值约 US$42.3M,约占其申报组合的 1.67%,在其申报持仓中市值排名第 19 位。 BRAIDWELL LP 最近 2 个申报季度中有 2 个季度披露了 RYTM 持仓,最早可追溯至 Q1 2026。

最新持仓 (Q2 2026)381.13K 股
申报持仓市值$42.32M
组合权重1.67%
首次申报Q1 2026
最近变动增持
更新于2026-10-24

最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR

BRAIDWELL LP 对 RYTM 的持仓演变

BRAIDWELL LP 于 Q1 2026 首次披露 RYTM 持仓:310,628 股(约 US$27.0M)。 该持仓在 Q2 2026 达到峰值 381,128 股,市值约 US$42.3M。 在 2 次申报中,BRAIDWELL LP 1 次增持、0 次减持、0 次保持不变。 最近一期申报(Q2 2026)显示持股 381,128 股、市值约 US$42.3M,环比增持 70,500 股。。

逐季持仓明细

季度股数金额变化
Q1 2026 310.63K $27.02M 新进
Q2 2026 381.13K $42.32M 增持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 RYTM 与 13F 数据

RYTM(RHYTHM PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 51 只申报持有 RYTM,申报仓位最大的包括:RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 RYTM 的基金

查看 RYTM 的全部基金持有人 →

常见问题

How long has BRAIDWELL LP held RYTM?

BRAIDWELL LP has disclosed RYTM holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is BRAIDWELL LP's current position in RYTM?

As of Q2 2026, BRAIDWELL LP holds 381.13K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $42.32M, representing 1.67% of its reported portfolio and ranking #19.

Has BRAIDWELL LP been buying or selling RYTM?

In the latest 13F filing (Q2 2026), BRAIDWELL LP increased its position in RYTM. The position peaked in Q2 2026 at 381.13K shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.